{
    "name": "fluorodeoxyphenylalanine 18F-DOPA",
    "comment": "Rx",
    "other_names": [
        "Fluorodopa F18"
    ],
    "classes": [
        "Diagnostic Imaging Agents"
    ],
    "source": "https://reference.medscape.com/drug/fluorodopa-f18-fluorodeoxyphenylalanine-18f-dopa-4000031",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women",
            "Additionally, animal reproductive and developmental toxicity studies have not been conducted",
            "All radiopharmaceuticals have potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiation dose"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "No data are available regarding the presence in human milk, the effects of the drug on the breastfed child, or on milk production",
            "Minimize exposure to infant by temporarily discontinuing breastfeeding",
            "Advise lactating women to pump and discard breastmilk for at least 24 hr (12 half-lives) after administration"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use contributes to a patientâ€™s overall long-term radiation exposure, which is associated with an increased risk of cancer; use smallest dose necessary for imaging and ensure safe handling to protect the patient and healthcare worker"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Aromatic L-amino acid decarboxylase (AADC) inhibitors ",
                        "Use of AADC inhibitors (eg, carbidopa, benserazide) may increase fluorodeoxyphenylalanine 18F-DOPA bioavailability to the brain by inhibiting peripheral decarboxylase activity and restricting peripheral metabolism",
                        "This interaction is beneficially used as part of the imaging procedure",
                        "Drugs for treating Parkinson disease",
                        "Dopamine agonists, dopamine reuptake inhibitors, dopamine-releasing agents (DRAs), peripheral catechol-O-methyltransferase (COMT) inhibitors, and monoamine oxidase (MAO) inhibitors",
                        "Whether discontinuation of these drugs prior to fluorodeoxyphenylalanine 18F-DOPA administration may minimize the interference with an image is not fully known; however, if use of these drugs can be safely suspended, discontinue use 12 hr before the imaging study"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Pain",
            "percent": null
        }
    ]
}